OncoMatch/Clinical Trials/NCT06326411
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Is NCT06326411 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NST-628 for oncology.
Treatment: NST-628 — This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Non-Small Cell Lung Carcinoma
Glioblastoma
Tumor Agnostic
Biomarker criteria
Required: NRAS activating mutation
Activating NRAS mutations
Required: BRAF select alterations
Select BRAF alterations
Required: KRAS activating mutation
Solid tumors with KRAS activating mutations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: MEK inhibitor
prior treatment with any MEK or BRAF inhibitor
Cannot have received: BRAF inhibitor
prior treatment with any MEK or BRAF inhibitor
Cannot have received: chemotherapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: radiation therapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: gene therapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: vaccine therapy
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: antibody-drug conjugate
Exception: within 28 days of Cycle 1 Day 1
Chemotherapy, radiation, gene therapy, vaccine therapy, or anti-cancer antibodies / ADCs within 28 days of Cycle 1 Day 1
Cannot have received: targeted small molecule agent
Exception: within 14 days or 5 half-lives of Cycle 1 Day 1
Targeted small molecule agents within 14 days or 5 half-lives of Cycle 1 Day 1
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- UCLA Hematology/Oncology · Westwood, Los Angeles, California
- Sarah Cannon Research Institute at Health ONE · Denver, Colorado
- Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify